Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2010

Abstract excerpt

PURPOSE: The Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) project aims to additionally explore the data of the two large, randomized, cooperative-group studies comparing two doses of imatinib (400 mg daily v twice daily) in 1,640 patients with advanced GIST. METHODS: End points were progression-free survival (PFS) and overall survival (OS). Investigated cofactors included age, sex, performance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Disease-Free Survival
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Neoplasm Metastasis

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 20124181
DOI: 10.1200/JCO.2009.24.2099
PMCID: PMC2834472

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.PMID 20124181Read ↗

The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.Semantic proximity Read ↗

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.Semantic proximity Read ↗

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.Semantic proximity Read ↗

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.Semantic proximity Read ↗

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.Semantic proximity Read ↗

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.Semantic proximity Read ↗

Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.Semantic proximity Read ↗

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.